114 results found.
          
Company Revenue 2015: SeaSpine
4Q15: $34.7MM, -1.2% 2015: $133.2MM, -3.9% (U.S. $120.3MM, -3.2%; ex-U.S. $12.9MM, -9.7%) All growth for 4Q and full year is as-reported. ORTHOWORLD estimates 2015 segment revenue and as-reported growth as follows: Spine $65.9MM, -7.3% Orthobiologi...
Company Revenue 2015: Integra LifeSciences
2015: $89.6MM, +23% 4Q15: $26.7MM, +34.3% ORTHOWORLD estimates 2015 segment revenue and as-reported growth as follows. Joint Reconstruction $17.8MM, +22.3% Trauma $71.9MM, +23.8%   Notes overall revenue headwind...
36 Acquisitions Completed in 2015
Acquistion activity remained consistent in 2015 vs. previous years, with ORTHOWORLD reporting 36 completed transacations by device and supplier companies, as compared to 37 in both 2014 and 2013. About 22 percent of the acqusitions took place in the spine segment, while another 22 percent were ...
SeaSpine Reports Preliminary 4Q15 and 2015 Revenue
SeaSpine announced preliminary 2015 sales of ~US $133.5MM and 4Q15 sales of ~$35MM, flat v...
2015: Product Launch Recap
By Carolyn LaWell To begin 2016, let’s consider the new products that entered the market in 2015 and are expected to fuel growth in the new year. We’ve broken them down by market segment. A complete list of 2015 product launch announcements...
SeaSpine Reports 3Q15 Revenue
SeaSpine announced 3Q15 revenue of US $32.7MM, -3% from 3Q14, and YTD 2015 revenue of $98.4MM, -5% vs. the prio...
Integra LifeSciences Posts 3Q15 Revenue
Integra LifeSciences posted 3Q15 Orthopedics and Tissue Technologies revenue of US $79.2MM, +32% vs. 3Q14.
SeaSpine Launches Cambria NanoMetalene Interbody Device
SeaSpine launched the Cambria™ NanoMetalene® cervical interbody device, indicated as an
NASS Preview: Products and Companies to Watch
By Julie Vetalice Spine-centric product news and personnel announcements are ramping up as we near the mid-October annual meeting of NASS, the North American Spine Society. Recent analyst notes suggest that pure-play companies continue to outperform larger diversifi...
NASS PREVIEW: A Guide to the Recently-merged in Spine
Who bought whom? A look at mergers and other initiatives that are changing up the names behind the products at this year’s NASS meeting. Amendia + Baxano + Custom Spine + SpineSelect Amendia has logged the most acquisitions in the space ...
BARE BONES® - August 13, 2015
SeaSpine announced 2Q15 revenue of US $33.5MM, -6% from 2Q14. (Orthobiologics $17.0MM, +1%; Spinal Fusion Hardware $16.5MM, -13%) (
BARE BONES® - August 11, 2015
SeaSpine launched the Ventura™ NanoMetalene® transforaminal intervertebral body fusion device, featuring convex surfaces, multiple footprints and a large graft aperture for autogenous b...
BARE BONES® - July 30, 2015
SeaSpine announced preliminary 2Q15 revenue of US $33.5MM, -6% from 2Q14. (Orthobiologics $17.0MM, +1%; Spinal Fusion Hardware $16.5MM, -13%) (
The Consolidation Climate: What Trends Prevail?
By Carolyn LaWell Through the first half of 2015, the number of merger and acquisition transactions closed has kept pace with the amount of deals that took place during the same time periods in ...
BARE BONES® - July 2, 2015
Integra LifeSciences completed the spin-off of its SeaSpine orthobiologics and spinal fusion hardware business. (
BARE BONES® - June 8, 2015
Integra LifeSciences (IART) intends to complete its SeaSpine spin-off on 7/1/15. SeaSpine will be an independent, publicly-traded company trading on Nasdaq as SPNE, and will own IART's orthobiologics a...
BARE BONES® - April 30, 2015
Integra LifeSciences appointed Keith Valentine as Chief Executive Officer and John Bostjancic as Chief Financial Officer of its SeaSpine spinoff. (
2014 Revenue: Bacterin
4Q14 revenue: $9.1MM, +10% 2014 revenue: $35.3MM, +7%   3Demin portfolio generated >$250,000 since launch Claims total market for products (like OsteoSponge, 3Demin) is ~$410MM Claims share for demineralized bone matrix p...
2014 Revenue: Integra LifeSciences
4Q14 revenue: $98.1MM, flat (U.S. $83.4MM, +2%; ex-U.S. $14.7MM, -13%) U.S. Extremities $40.3MM, +17% U.S. Spine & Other $43.1MM, -8%   New product introductions (Titan Shoulder, Total Foot System 2, Freedom Wrist) + ad...
2014: A Recap of Strategic Activities
To begin 2015, let’s look back at what fueled growth in 2014. Here, we present companies that ha...
2014: A Recap of Strategic Activities in Orthobiologics
Editor’s Note: This segment-specific article is excerpted from the full version, covering major market segments, appearing in ORTHOKNOW January 2015. To begin...
2014: A Recap of Strategic Activities in Spine
Editor’s Note: This segment-specific article is excerpted from the full version, covering major market segments, appearing in ORTHOKNOW January 2015. To begin...
BARE BONES® - November 3, 2014
Integra LifeSciences will spin off its spine business to a publicly-traded company called SeaSpine, focused on developing, marketing and selling hardware and orthobiologics. Integra will conti...
3Q14 Revenue: Integra LifeSciences
$91.6MM, -7% (U.S. $78.6MM, -4%; ex-U.S. $12.9MM, -23%) U.S. Extremities $36.7MM, +15% U.S. Spine & Other $42.0MM, -11% (Spine -3%, Private Label +26%)   Strong growth from Total Foot System and shoulder launch, Premier...
First Look at Quarterly Results: 1Q12 vs. 1Q11
ORTHOWORLD’s preliminary estimates place overall 1Q12 market growth at 3% over 1Q11, as shown in Exhibit 1. Performance highlights follow and pertain to 1Q12, unless noted otherwise. Exhibit 1 Orthopaedic Sales1 Increase...
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2020 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group